Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, ...

Geoff Meacham, Citi analyst, joins 'Fast Money' to talk what the year ahead holds for competition in the obesity drug market.

The about-$1 billion deal could come imminently.

Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop ...

These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.

An approval of Lilly's pill, along with its current strength in the weight loss market, could equal revenue growth well into ...

The terms of the agreement entail that Eli Lilly and Company (NYSE:LLY) would acquire all the outstanding shares of Ventyx ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

FDA oral Wegovy, solid fundamentals, and low P/E vs. Eli Lilly. Click for this updated look at NVO stock prospects as ...

According to a story in the French-language newspaper La Tribune on December 24, 2025, there have been rumors that Eli Lilly ...

The big lure for Eli Lilly to build a $6.5 billion pharmaceuticals plant in Houston is now official — and details are out on ...

The project was secured by a Jobs, Energy, Technology and Innovation Act (JETI) tax agreement, which includes a school tax ...